ERBB2 and breast carcinoma: Monoclonal antibodies globally demonstrated to be ineffective in HER2-low breast cancer, because their activity relies mainly on the blockade of aberrant HER2 signaling via dimerization inhibition, HER2 internalization, and antibody-dependent cellular cytotoxicity (Hudis 2007; Eiger et al., 2021).